FDA Approves Sanofi Aventis's Lovenox
Lovenox is an anticoagulant (blood thinner) that prevents the formation of blood clots.
Lovenox is used to treat or prevent a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism). A DVT can occur after certain types of surgery, or in people who are bed-ridden due to a prolonged illness.
Lovenox is also used to prevent blood vessel complications in people with certain types of angina (chest pain) or heart attack.
Lovenox (enoxaparin sodium) Injection has been approved for the extended prevention of deep-vein thrombosis (DVT) following hip replacement surgery. It was previously approved for use in a hospital setting, and is the first low-molecular-weight heparin to be approved for once a day at home use.
Enoxaparin is used to prevent blood clots in the leg in patients who are on bedrest or who are having hip replacement, knee replacement, or stomach surgery. It is used in combination with aspirin to prevent complications from angina (chest pain) and heart attacks. It is also used in combination with warfarin to treat blood clots in the leg. Enoxaparin is in a class of medications called low molecular weight heparins. It works by stopping the formation of substances that cause clots.